2 Problems and (Maybe) 1 Opportunity for Moderna This Summer
Headwinds eventually batter all stocks, even a fiercely expanding and globally relevant biotech like Moderna (NASDAQ: MRNA). And despite a run-up of more than 400% in the past three years, the ascendant coronavirus vaccine developer might soon be facing a combination of issues that'll give way to a serious slowdown.
Nonetheless, there's also the chance of turning at least one of the potential lemons into the sweet lemonade of even higher earnings, and it's entirely plausible that the company will be in better shape in the fall than it is at the moment. So let's get a better understanding of which obstacles are likely to be opportunities, and which aren't.
Image source: Getty Images.
Source Fool.com
